ATE202785T1 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Info

Publication number
ATE202785T1
ATE202785T1 AT95904405T AT95904405T ATE202785T1 AT E202785 T1 ATE202785 T1 AT E202785T1 AT 95904405 T AT95904405 T AT 95904405T AT 95904405 T AT95904405 T AT 95904405T AT E202785 T1 ATE202785 T1 AT E202785T1
Authority
AT
Austria
Prior art keywords
growth hormone
pct
hormone releasing
compounds
date jun
Prior art date
Application number
AT95904405T
Other languages
English (en)
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thogersen
Birgit Sehested Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143893A external-priority patent/DK143893D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE202785T1 publication Critical patent/ATE202785T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95904405T 1993-12-23 1994-12-22 Verbindungen mit wachstumshormon-freisetzenden eigenschaften ATE202785T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK143893A DK143893D0 (de) 1993-12-23 1993-12-23
DK7594 1994-01-17
DK78194 1994-06-30
DK116594 1994-10-07
PCT/DK1994/000486 WO1995017422A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ATE202785T1 true ATE202785T1 (de) 2001-07-15

Family

ID=27439242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95904405T ATE202785T1 (de) 1993-12-23 1994-12-22 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Country Status (18)

Country Link
US (1) US5854211A (de)
EP (1) EP0736038B1 (de)
JP (1) JP3759748B2 (de)
CN (1) CN1052730C (de)
AT (1) ATE202785T1 (de)
AU (1) AU683121B2 (de)
CA (1) CA2179598A1 (de)
CZ (1) CZ291382B6 (de)
DE (1) DE69427650T2 (de)
FI (1) FI962591A0 (de)
HU (1) HU221092B1 (de)
IL (1) IL112111A (de)
NO (1) NO315611B1 (de)
PL (1) PL181286B1 (de)
RU (1) RU2167881C2 (de)
TW (1) TW438810B (de)
UA (1) UA45962C2 (de)
WO (1) WO1995017422A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
KR20010034198A (ko) 1998-01-16 2001-04-25 한센 핀 베네드 성장 호르몬 방출성을 가지는 화합물
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
CA2340095A1 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
EP1158996A4 (de) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd Neue amidderivate als wachstumshormonsekretionsförderer
AU5630800A (en) * 1999-06-22 2001-01-09 Arno F Spatola Antimicrobial agents
ATE309358T1 (de) * 1999-07-26 2005-11-15 Baylor College Medicine Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
AU2001252958A1 (en) * 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
DK1372688T3 (da) * 2001-03-08 2008-08-25 Univ Tulane Somatostatin-antagonister
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US20070281935A1 (en) * 2004-05-25 2007-12-06 Pfizer Inc. Use
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2644618B1 (de) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. Intermediaten für die Synthese von Makrozyklische Ghrelin-Rezeptormodulatoren
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2016129645A1 (ja) 2015-02-10 2016-08-18 富士フイルム株式会社 光学部材、光学素子、液晶表示装置および近接眼光学部材
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
US5480869A (en) * 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5470753A (en) * 1992-09-03 1995-11-28 Selectide Corporation Peptide sequencing using mass spectrometry
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
ATE197158T1 (de) * 1993-12-23 2000-11-15 Novo Nordisk As Verbindungen mit wachstumshormonfreisetzenden eigenschaften

Also Published As

Publication number Publication date
HU221092B1 (en) 2002-08-28
EP0736038B1 (de) 2001-07-04
FI962591L (fi) 1996-06-20
CZ291382B6 (cs) 2003-02-12
US5854211A (en) 1998-12-29
EP0736038A1 (de) 1996-10-09
RU2167881C2 (ru) 2001-05-27
PL181286B1 (pl) 2001-07-31
PL315114A1 (en) 1996-10-14
AU1310695A (en) 1995-07-10
HU9601740D0 (en) 1996-08-28
NO315611B1 (no) 2003-09-29
CN1052730C (zh) 2000-05-24
CN1138334A (zh) 1996-12-18
TW438810B (en) 2001-06-07
WO1995017422A1 (en) 1995-06-29
IL112111A0 (en) 1995-03-15
DE69427650D1 (de) 2001-08-09
JP3759748B2 (ja) 2006-03-29
CZ183396A3 (en) 1997-02-12
NO962664L (no) 1996-08-23
UA45962C2 (uk) 2002-05-15
DE69427650T2 (de) 2001-11-22
IL112111A (en) 2000-07-16
JPH09506873A (ja) 1997-07-08
FI962591A7 (fi) 1996-06-20
NO962664D0 (no) 1996-06-21
HUT74820A (en) 1997-02-28
CA2179598A1 (en) 1995-06-29
FI962591A0 (fi) 1996-06-20
AU683121B2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
ATE202785T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
PT689550E (pt) Peptidos antimicrobianos de neutrofilos bovinos
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE439346T1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
DE69531098D1 (de) Piperidine und pyrrolidine
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
ATE500269T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69531150D1 (de) Verwendung von biopolymeren zur behandlung der muskeln
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
ATE272651T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
NZ323207A (en) Hemoregulatory compounds
DE69503635D1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
TH32887A (th) สารประกอบทางเคมี